375 related articles for article (PubMed ID: 16950021)
1. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
2. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
4. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
6. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia.
Gustavsson I; Juko-Pecirep I; Backlund I; Wilander E; Gyllensten U
J Clin Virol; 2009 Jun; 45(2):85-9. PubMed ID: 19451022
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience.
Lonky NM; Mahdavi A; Wolde-Tsadik G; Bajamundi K; Felix JC
J Low Genit Tract Dis; 2010 Jul; 14(3):200-5. PubMed ID: 20592555
[TBL] [Abstract][Full Text] [Related]
8. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.
Castle PE; Schiffman M; Burk RD; Wacholder S; Hildesheim A; Herrero R; Bratti MC; Sherman ME; Lorincz A
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1394-9. PubMed ID: 12433717
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus testing for primary screening of cervical cancer precursors.
Ratnam S; Franco EL; Ferenczy A
Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):945-51. PubMed ID: 11008913
[TBL] [Abstract][Full Text] [Related]
10. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus testing for primary cervical cancer screening.
Grce M; Davies P
Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
[TBL] [Abstract][Full Text] [Related]
12. HPV DNA testing in the triage of atypical squamous cells of undetermined significance (ASCUS): cost comparison of two methods.
Layfield LJ; Qureshi MN
Diagn Cytopathol; 2005 Aug; 33(2):138-43. PubMed ID: 16007672
[TBL] [Abstract][Full Text] [Related]
13. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set.
Jones J; Powell NG; Tristram A; Fiander AN; Hibbitts S
J Clin Virol; 2009 Jun; 45(2):100-4. PubMed ID: 19394266
[TBL] [Abstract][Full Text] [Related]
15. Chapter 10: New dimensions in cervical cancer screening.
Cuzick J; Mayrand MH; Ronco G; Snijders P; Wardle J
Vaccine; 2006 Aug; 24 Suppl 3():S3/90-7. PubMed ID: 16950022
[TBL] [Abstract][Full Text] [Related]
16. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.
Wright TC; Schiffman M; Solomon D; Cox JT; Garcia F; Goldie S; Hatch K; Noller KL; Roach N; Runowicz C; Saslow D
Obstet Gynecol; 2004 Feb; 103(2):304-9. PubMed ID: 14754700
[TBL] [Abstract][Full Text] [Related]
17. A study of the impact of adding HPV types to cervical cancer screening and triage tests.
Schiffman M; Khan MJ; Solomon D; Herrero R; Wacholder S; Hildesheim A; Rodriguez AC; Bratti MC; Wheeler CM; Burk RD; ;
J Natl Cancer Inst; 2005 Jan; 97(2):147-50. PubMed ID: 15657345
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic human papillomavirus testing in an adolescent population with atypical squamous cells of undetermined significance.
Fletcher AH; Wilkinson EJ; Knapik JA
J Low Genit Tract Dis; 2009 Jan; 13(1):28-32. PubMed ID: 19098603
[TBL] [Abstract][Full Text] [Related]
19. HPV testing: where are we now?
Bovicelli A; Bristow RE; Montz FJ
Anticancer Res; 2000; 20(6C):4673-80. PubMed ID: 11205199
[TBL] [Abstract][Full Text] [Related]
20. The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment.
Ronco G; Brezzi S; Carozzi F; Dalla Palma P; Giorgi-Rossi P; Minucci D; Naldoni C; Segnan N; Zappa M; Zorzi M; Cuzick J;
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S230-2. PubMed ID: 17822751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
